Loading...

CAPITAL INCREASE OF LABIANA HEALTH: PRACTICAL GUIDE FOR SHAREHOLDERS ON SUBSCRIPTION RIGHTS

Home / News / CAPITAL INCREASE OF LABIANA HEALTH: PRACTICAL GUIDE FOR SHAREHOLDERS ON SUBSCRIPTION RIGHTS

CAPITAL INCREASE OF LABIANA HEALTH: PRACTICAL GUIDE FOR
SHAREHOLDERS ON SUBSCRIPTION RIGHTS

  • Labiana is publishing an informative guide to help its shareholders understand how subscription rights work and the different alternatives available during the capital increase.

On the occasion of the capital increase announced by Labiana Health on February 18, the company has in recent weeks received a number of enquiries from shareholders about how preferential subscription rights work and the different alternatives available during the process.

With the aim of making this easier to understand, the company has prepared a purely informative practical guide, which explains in simple terms how subscription rights work and what options a shareholder has during the capital increase subscribing for shares, selling rights, buying rights or not exercising them).

The document includes illustrative examples and a frequently asked questions section designed to help shareholders better understand the technical workings of the transaction.

It is important to remember that this guide is for information purposes only and does not in any way constitute financial advice or an investment recommendation. Each shareholder must make their own decisions independently and, if necessary, consult their custodian entity and their financial or tax advisers to analyse their particular situation.

You can download the Practical Guide for shareholders on the capital increase of Labiana Health here.

About Labiana

Labiana Health is a leading independent international laboratory in animal and human health, with an integrated structure, a diversified portfolio of products and businesses, and a broad client base of top-tier customers with whom it maintains long-term relationships of trust. Labiana has subsidiaries in Spain, Serbia, Turkey and Mexico, and production facilities located in Spain and Serbia. Products manufactured by Labiana are present in more than 150 markets, with registrations for its own products in over 90 countries. The group has two distinct yet complementary business lines: contract manufacturing in both the veterinary and human health fields, which provides stability and visibility of revenues; and the development, manufacturing and marketing of its own animal and human health products, which drive growth. The company was listed on BME Growth in June 2022, becoming the first veterinary company to go public on the BME Growth market in Spain.

Comments(0)

    Leave a Comment

    one × 4 =

    *

    Privacy overview

    This website uses cookies to offer you the best possible user experience. Cookies’ information is stored in your browser and performs functions such as recognizing when you return to our website or helping our team to understand which sections of the website you find most interesting and useful. More information in the privacy policy and cookie policy!